Fennec Pharma up after launch of hearing-loss therapy

Fennec Pharmaceuticals

17/10/2022 15:47

** Shares of Fennec Pharmaceuticals Inc  FENC.O  gain ~2% to
$8
    ** Co announces commercial launch and availability of its
therapy, Pedmark, in the U.S. to prevent chemotherapy-induced
hearing loss in children  urn:newsml:reuters.com:*:nGNX1pn76h
    ** Pedmark was approved by the U.S. FDA last month
 urn:newsml:reuters.com:*:nL4N30S21J
    ** Therapy can be used to reduce the risk of ototoxicity in
children aged one month and older who have undergone
chemotherapy using the drug cisplatin
    ** Including session moves, stock up ~82% YTD
 (Reporting by Raghav Mahobe)
 ((Raghav.Mahobe@thomsonreuters.com;))